Raises 2025 operating profit outlook to $1.055B-$1.405B from $895M-$1.365B. The company said, “The improved guidance is driven by higher total royalty revenues from DARZALEX.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s EPCORE® FL-1 Trial Achieves Key Milestones in Follicular Lymphoma
- Genmab says Phase 3 EPCORE FL-1 trial met dual primary endpoints
- Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer?
- AbbVie and Genmab’s Promising Update on B-Cell Lymphoma Treatment Study
- AbbVie and Genmab’s Promising Phase 3 Study for DLBCL Treatment